Tinostamustine is under clinical development by Mundipharma EDO and currently in Phase I for Mantle Cell Lymphoma.

CKD is developing non-hydroxamic acid (NHA)-based histone deacetylase 6 (HDAC6) inhibitors for non-oncology indications. CKD’s NHA inhibitors address the limitations of hydroxamic acid (HA ...

To address these changes, the team tested the administration of suberoylanilide hydroxamic acid (SAHA) during the restoration of blood flow. The drug successfully prevented some of the early ...